Is Inovio (NASDAQ:INO) Up 224% the Healthcare Move to Back, or Do Neurocrine (NASDAQ:NBIX), Tempus AI (NASDAQ:TEM) or Novo Nordisk (NYSE:NVO) Make a Better Case?

Vinay Lochav

05 November 2026 12:49 AM AEDT

Is Inovio (NASDAQ:INO) Up 224% the Healthcare Move to Back, or Do Neurocrine (NASDAQ:NBIX), Tempus AI (NASDAQ:TEM) or Novo Nordisk (NYSE:NVO) Make a Better Case?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Inovio (NASDAQ:INO) rose roughly 224% on November 2, 2026, from a pre-news level near USD 0.60 after the FDA granted Accelerated Approval to VOCERYQ.
Neurocrine Biosciences (NASDAQ:NBIX) gained 13.42% on November 3 as Revenue climbed 41% to USD 1,123 million, with Crenessity sales of USD 211 million, up 115%.
Tempus AI (NASDAQ:TEM) advanced 8.67% on November 2 after revenue grew 23% to USD 411.5 million and 2026 revenue guidance rose to USD 1.60 billion to USD 1.605 billion.
Novo Nordisk (NYSE:NVO) posted Wegovy pill sales of DKK 5,394 million and set its 2026 outlook at minus 2% to plus 2%, with shares up about 5% to 6% early on November 4.

Inovio (NASDAQ:INO): The Biggest Move on the Thinnest Evidence

Inovio (NASDAQ:INO) said on October 30, 2026 that the FDA had granted accelerated approval to VOCERYQ to reduce how often adults with recurrent respiratory papillomatosis need surgery, and published coverage showed the stock up roughly 224% on November 2. VOCERYQ is a plasmid DNA immunotherapy that encodes HPV-6 and HPV-11 antigens and is given with the CELLECTRA 5PSP device, which uses electrical pulses to help cells take up the DNA. In the RRP-001 trial, 7 of 26 patients in the efficacy population, or 27% with a 95% confidence interval of 12% to 48%, needed no surgical excision after 12 months. The trial was single-arm and open-label with 32 patients. Accelerated approval rests on an intermediate endpoint, so a confirmatory study is required, with a draft protocol due by the end of 2026 and a final protocol expected by mid-2027. Ordering and shipping are expected in about 60 days, with full launch in the first quarter of 2027. Inovio is a small cap, so a few trades can move the price, quoted moves can reverse, and a further Equity raise to fund the launch would dilute holders. Commercial risks include arriving second to market and the cost of building a sales force, with Syneos Health supporting field teams.

Neurocrine Biosciences (NASDAQ:NBIX): A Profitable Two-Drug Business

Neurocrine Biosciences (NASDAQ:NBIX) reported third-quarter 2026 results for the quarter ended September 30. Total revenue reached USD 1,123 million, up 41%. Ingrezza, its treatment for tardive dyskinesia and chorea in Huntington's disease, brought in USD 801 million, up 17%, while Crenessity, approved for classic congenital adrenal hyperplasia, delivered USD 211 million, up 115%. Non-GAAP Earnings were USD 3.29 a share against USD 2.17, and GAAP earnings of USD 1.96 fell from USD 2.04. The company raised its 2026 Ingrezza guidance to USD 2,900 million to USD 2,925 million from USD 2,825 million to USD 2,875 million, and the shares closed up 13.42% on November 3. Ingrezza made up about 71% of revenue and Crenessity about 19%, simple arithmetic. Ingrezza is growing more slowly than the company as a whole, payers press on pricing, and Crenessity serves a small patient population, so growth can slow once early patients are treated. The release gives no 2026 Crenessity range. The midpoint of the new Ingrezza range sits about USD 62.5 million above the old one, simple arithmetic, and the gap between non-GAAP and GAAP earnings was USD 1.33 a share, so the basis of comparison matters. A 13.4% gain also raises the bar for the next report.

Tempus AI (NASDAQ:TEM): Turning the Corner on One Measure

Tempus AI (NASDAQ:TEM) reported third-quarter results on November 2, 2026. Revenue was USD 411.5 million, up 23%, slightly above a consensus near USD 409 million. Diagnostics revenue was USD 303.5 million, up 20%, and data and applications revenue was USD 108.1 million, up 33%, about 26% of the total, simple arithmetic. Adjusted EBITDA of USD 25.6 million was the first positive quarter on that measure, though the GAAP net loss was USD 14.9 million, according to published coverage. Full-year adjusted EBITDA guidance was maintained at about USD 65 million, which implies the fourth quarter must stay positive. Cash and marketable securities were USD 854.4 million, and the shares closed up 8.67%. These figures come from published coverage of the call and release, which could not be matched to the full filing, so treat them as approximate. Data revenue depends on a few large pharmaceutical customers, reimbursement and regulatory decisions for tests are a swing factor, and a Shareholder vote on November 30 is the next catalyst. Oncology revenue was USD 172.6 million, up 28%, and hereditary testing USD 111.3 million, so most diagnostics revenue comes from two lines.

Novo Nordisk (NYSE:NVO): A Stabilising Year, Not a Growth Year

Novo Nordisk (NYSE:NVO) published third-quarter results on November 4, 2026. Net sales of DKK 79,195 million rose 4% at constant exchange rates, and adjusted operating profit of DKK 31,720 million rose 27%, helped by a weak comparison base that included about DKK 9 billion of transformation costs a year earlier. Wegovy pill sales were DKK 5,394 million after launches in the US, the UAE, the UK and Germany, with four more countries added. Reported operating profit fell 3% to DKK 23,011 million after DKK 8.7 billion of non-cash impairments, so the adjusted and reported pictures differ. The company lifted its 2026 outlook, but the range is minus 2% to plus 2% for adjusted sales and adjusted operating profit growth at constant rates, which describes a stabilising year. The release does not state the prior ranges, and no consensus comparison was available, so no beat or miss is stated. Shares rose roughly 5% to 6% in early trading per published coverage. Pricing pressure, competition in obesity, Supply and launch costs and Impairment charges are the risks. The impairments were DKK 4.6 billion on ziltivekimab and DKK 4.1 billion tied to right-sizing the Manufacturing network, and a share repurchase programme started on May 6, 2026.

Where Things Stand

The strongest case rests on Neurocrine, because its move follows 41% revenue growth, a stated guidance raise and a profitable base, though it depends on two drugs. Novo Nordisk (NYSE:NVO) has a clear launch story but a flat outlook range and a reported profit decline. Tempus has improving but thin profit and approximate figures. Inovio's 224% is the biggest move on the thinnest evidence, a 32-patient single-arm trial and a small-cap stock. Neurocrine Biosciences (NASDAQ:NBIX) has the most documented numbers. Inovio (NASDAQ:INO) has the highest Reversal risk, because a few trades can move a thin stock. Investors should separate approvals and launches from profit. None of these moves is a forecast.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.